Dauntless Investment Group’s Cue Biopharma CUE Stock Holding History

Dauntless Investment Group’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-81	Closed	-$555	–	82
2026 Q1	$555	Buy	+81	New	+$756	﹤0.01%	66

Other funds holding CUE

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Squadron Capital Management Westmont, Illinois $322M AUM

Dauntless Investment Group's CUE Position: Q2 2026 in Review

Dauntless Investment Group sold out of Cue Biopharma (CUE) in Q2 2026, closing a stake of 81 shares — an estimated $555 sold.

Dauntless Investment Group first reported a position in CUE in Q1 2026 and held it in 1 quarter. The position peaked at $555 in Q1 2026. 49 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

Dauntless Investment Group reported no remaining Cue Biopharma position as of Q2 2026 after selling out during the quarter.
Dauntless Investment Group sold 81 Cue Biopharma shares in Q2 2026, an estimated $555.
Dauntless Investment Group first reported a position in Cue Biopharma in Q1 2026 and held it in 1 quarter.
Dauntless Investment Group's Cue Biopharma position peaked at $555 in Q1 2026.
49 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on Dauntless Investment Group's 13F filing for Q2 2026, filed 13 Aug 2026.